Dolutegravir with lamivudine for treating Human Immunodeficiency Virus type 1 (HIV-1) infection

Published on 19 Dec 2022
Last Updated on 19 Dec 2022

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

• Dolutegravir 50 mg/lamivudine 300 mg tablet for treating Human Immunodeficiency Virus type 1 (HIV-1) infection

in view of acceptable proposal from the company.

Funding status

Dolutegravir 50 mg/lamivudine 300 mg tablet is recommended for inclusion on the MOH Standard Drug List (SDL) from 1 February 2023.
Information on antiretroviral therapies previously recommended by the Drug Advisory Committee can be found in the Technology Guidance published on 1 September 2020 (Antiretroviral therapies for treating Human Immunodeficiency Virus type 1 (HIV-1) infection).

Dolutegravir with lamivudine for treating Human Immunodeficiency Virus type 1 (HIV-1) infection (19 December 2022) [PDF, 102 KB]